Amiloride-sensitive sodium channel subunit beta mRNA (SCNN1B)

The Amiloride-sensitive sodium channel subunit beta (SCNN1B) mRNA encodes one of the three essential subunits (alpha, beta, and gamma) that form the functional epithelial sodium channel (ENaC) complex (UniProt P51168). ENaC is a non-voltage-gated, amiloride-sensitive ion channel located in the apical membrane of epithelial cells, particularly in the distal nephron of the kidney and the respiratory tract (NCBI Gene 6338). Its primary biological function is to mediate the rate-limiting step of sodium reabsorption, which is crucial for maintaining total body salt and water balance, as well as regulating blood pressure and airway surface liquid volume. Mutations in the SCNN1B gene are linked to severe clinical conditions: gain-of-function mutations cause Liddle syndrome, characterized by severe hypertension and hypokalemia, while loss-of-function mutations result in pseudohypoaldosteronism type 1B (StatPearls: Liddle Syndrome). In the context of cystic fibrosis and other muco-obstructive lung diseases, SCNN1B mRNA is a therapeutic target for antisense oligonucleotides (ASOs) like IONIS-ENAC-2.5Rx, which aim to reduce ENaC protein expression to prevent sodium hyperabsorption and improve lung hydration (PMID: 28801156). By lowering the levels of SCNN1B mRNA, these therapies seek to restore mucociliary clearance and reduce the risk of chronic respiratory infections (ClinicalTrials.gov: NCT03647358).

Other names

Beta-ENaCENaCbSodium channel epithelial 1 subunit betaNonvoltage-gated sodium channel 1 subunit betaSCNN1BSCNEBB-ENaC

Antisense oligonucleotide-mediated degradation of mRNA via RNase H1 recruitment to reduce protein expression; direct pore blockade of the resulting channel protein.